SCHEMBL9613337

SCHEMBL9613337

CCn1c(C(=O)O)cc2cc(C)ccc21

nearest known ligand 0.62

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GPR35 Q9HC97 3/20 0.62
CCR2 P41597 6/20 0.49
CCR9 P51686 1/20 0.48
KMT2A Q03164 3/20 0.46
MEN1 O00255 2/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
THRB P10828 2/20 0.45
KDM4E B2RXH2 1/20 0.45
MAPT P10636 1/20 0.45
HPGD P15428 1/20 0.45
RAB9A P51151 1/20 0.45
LMNA P02545 1/20 0.45
TP53 P04637 1/20 0.45
RXFP1 Q9HBX9 1/20 0.45
GFER P55789 1/20 0.44
ALDH1A1 P00352 1/20 0.43
CYP1A2 P05177 1/20 0.43
POLB P06746 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13802535 0.88 PLA2G4A (0.51) GPR35CCR2CCR9KMT2AMEN1
SCHEMBL4370468 0.85 ALDH1A1 (0.50) GPR35CCR2CCR9KMT2AMEN1
SCHEMBL1553069 0.84 GPR35 (0.67) GPR35CCR2KMT2AMEN1KDM4E
SCHEMBL4367809 0.84 GPR35 (0.47) GPR35CCR2CCR9KMT2AMEN1
SCHEMBL4363318 0.84 PLA2G4A (0.52) GPR35CCR2CCR9KMT2AMEN1
SCHEMBL27718204 0.83 GPR35 (0.49) GPR35CCR2CCR9KMT2AMEN1
SCHEMBL4361805 0.83 PLA2G4A (0.53) GPR35CCR2KMT2AMEN1L3MBTL1
SCHEMBL38664558 0.83 MCL1 (0.65) GPR35CCR2CCR9KDM4EHPGD
SCHEMBL708583 0.83 MCL1 (0.65) GPR35CCR2CCR9KDM4EHPGD
SCHEMBL700700 0.83 CCR2 (0.65) GPR35CCR2CCR9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1727797-B1 PROCESS FOR CROSS COUPLING INDOLES BOEHRINGER INGELHEIM PHARMA (US) 2012-05-30 EP disclosed
EP-2335700-A1 Hepatitis C virus polymerase inhibitors with a heterobicylic structure BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 2011-06-22 EP disclosed
US-7893084-B2 Viral polymerase inhibitors BOEHRINGER INGELHEIM CANADA LTD. (CA) 2011-02-22 US disclosed
US-20090087409-A1 Viral Polymerase Inhibitors BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 2009-04-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090087409-A1 Viral Polymerase Inhibitors NR2C2, NR4A1, MED25 GPR35 2444/4885CCR2 400/4885CCR9 453/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.